June 13, 2018 – Dr O’Neill brings two decades of cancer drug development and seed stage investment experience, as well as an extensive business network in pharma and biotech.
Read More from FACIT Appoints Biotech Veteran Dr. David O’Neill as President
May 1, 2018 – FACIT looks forward to working with Dr. Radvanyi on translating Ontario’s breakthrough oncology innovations.
Read More from OICR Welcomes Former Merck IO Executive as new President
April 12, 2018 – Biotechnology competition modeled after popular TV program Dragons’ Den.
Read More from Winner of 2018 Falcons’ Fortunes Pitch Competition Announced
December 14, 2017 – We hope 2017 was a prosperous year for you, our partners in health innovation. While FACIT had many successes this year..
December 9, 2017 – Jeff was a fantastic leader in the OICR-FACIT family and the broader Ontario life sciences community.
December 6, 2017 – The Clinical Therapeutics Innovation Pipeline (CTIP) will support the local translation of Ontario discoveries into therapies with the potential for improving the lives of patients with cancer. Ten projects were selected in this highly competitive funding round, and reflect the strength of the province’s collaborative network and drug discoveries.
Read More from FACIT Features: OICR Launches CTIP Initiative
November 21, 2017 – New Trustees join existing Trustees, Mr. Greg Gubitz and Mr. John Morrison, bringing additional financial, entrepreneurial and biotech industry expertise.
Read More from FACIT Welcomes Kevin Empey, Cynthia Goh and Shana Kelley to the Board of Trustees
October 11, 2017 – Turnstone Biologics, a startup co-founded by FACIT, announced a research, option and license agreement with AbbVie Inc. for up to three of Turnstone’s next-gen oncolytic viral immunotherapies. This partnership deepens the Ontario roots established by FACIT and its co-founders, expanding the scale of innovative research and local career opportunities for scientists.
Read More from FACIT Features: Turnstone and AbbVie Announce Collaboration
September 25, 2017 – FACIT congratulates Fusion on completing the second closing of their Series A, now oversubscribed at US$46M, with new investors joining including Adams Street Partners, Seroba Life Sciences, and Varian Medical Systems Inc. FACIT participated in both, this latest closing and as an early seed investor in Fusion.
Read More from FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A
July 18, 2017 – FACIT is expanding and updating its database of US-based industry advisors for roles ranging from investment diligence to full time management roles in Ontario-based biotech start-ups.